Subscribe
bee32
bee32 / iStockphoto.com
20 December 2017Americas

PTAB institutes IPRs on Sanofi patents

The US Patent Trial and Appeal Board (PTAB) has instituted inter partes reviews (IPRs) of two patents owned by Sanofi covering Lantus (insulin glargine injection).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Sanofi wins SCOTUS stay of Lantus patent dispute
13 February 2020   Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan.
Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Sanofi wins SCOTUS stay of Lantus patent dispute
13 February 2020   Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan.
Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.

More on this story

Big Pharma
Sanofi wins SCOTUS stay of Lantus patent dispute
13 February 2020   Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan.
Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
Sanofi sues Merck over Lantus patents
21 September 2016   Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB